Aarti Pharmalabs Limited (AARTIPHARM) - Total Liabilities
Based on the latest financial reports, Aarti Pharmalabs Limited (AARTIPHARM) has total liabilities worth Rs-19.90 Billion INR (≈ $-215.20 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aarti Pharmalabs Limited - Total Liabilities Trend (2020–2025)
This chart illustrates how Aarti Pharmalabs Limited's total liabilities have evolved over time, based on quarterly financial data. See Aarti Pharmalabs Limited (AARTIPHARM) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Aarti Pharmalabs Limited Competitors by Total Liabilities
The table below lists competitors of Aarti Pharmalabs Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Redwood Trust Inc
NYSE:RWT
|
USA | $25.86 Billion |
|
Complete Logistic Services Bhd
KLSE:5136
|
Malaysia | RM67.56 Million |
|
Algoma Central Corporation
TO:ALC
|
Canada | CA$762.36 Million |
|
Shanghai Hollywave Electronic System Co. Ltd. A
SHG:688682
|
China | CN¥228.04 Million |
|
Hubei Century Network Technology Co Ltd
SHE:300494
|
China | CN¥136.87 Million |
|
Evergent Investments SA
RO:EVER
|
Romania | RON637.62 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$454.35 Million |
|
Guizhou Transp Planning
SHG:603458
|
China | CN¥2.70 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Aarti Pharmalabs Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AARTIPHARM market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | N/A | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aarti Pharmalabs Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aarti Pharmalabs Limited (2020–2025)
The table below shows the annual total liabilities of Aarti Pharmalabs Limited from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs9.16 Billion ≈ $99.12 Million |
+11.08% |
| 2024-03-31 | Rs8.25 Billion ≈ $89.23 Million |
+20.35% |
| 2023-03-31 | Rs6.86 Billion ≈ $74.14 Million |
+4.91% |
| 2022-03-31 | Rs6.53 Billion ≈ $70.67 Million |
+2807768.13% |
| 2021-03-31 | Rs232.71K ≈ $2.52K |
+24.61% |
| 2020-03-31 | Rs186.75K ≈ $2.02K |
-- |
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous sys… Read more